It has been theorized that poor EOC patient responses are due to the unique tumor microenvironment (TME), higher levels of regulatory T cells (Tregs) in ovarian tumors, and barriers in identification of patients who will benefit most from PD-1 therapy. Here, PDCD1 is linked to ovarian neoplasm.